Healthcare provider profile · identity verified

John A Halerz, M.D.

Family Practice · ROCHESTER, MN · NPI 1114375532

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	694	187
Lisinopril	Lisinopril	354	102
Amlodipine Besylate	Amlodipine Besylate	344	103
Losartan Potassium	Losartan Potassium	298	91
Levothyroxine Sodium	Levothyroxine Sodium	292	79
Omeprazole	Omeprazole	290	74
Metoprolol Succinate	Metoprolol Succinate	246	65
Simvastatin	Simvastatin	245	68
Gabapentin	Gabapentin	208	50
Metformin Hcl Er	Metformin Hcl	205	63
Hydrochlorothiazide	Hydrochlorothiazide	156	48
Tamsulosin Hcl	Tamsulosin Hcl	156	46
Eliquis	Apixaban	150	34
Rosuvastatin Calcium	Rosuvastatin Calcium	150	47
Warfarin Sodium	Warfarin Sodium	138	33
Trazodone Hcl	Trazodone Hcl	128	33
Furosemide	Furosemide	123	37
Metformin Hcl	Metformin Hcl	123	36
Metoprolol Tartrate	Metoprolol Tartrate	117	32
Allopurinol	Allopurinol	112	32
Pantoprazole Sodium	Pantoprazole Sodium	86	29
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	84	26
Fluticasone Propionate	Fluticasone Propionate	80	26
Glipizide Er	Glipizide	79	23
Sertraline Hcl	Sertraline Hcl	76	18
Famotidine	Famotidine	75	22
Finasteride	Finasteride	70	18
Chlorthalidone	Chlorthalidone	65	20
Duloxetine Hcl	Duloxetine Hcl	64	16
Jardiance	Empagliflozin	60	15
Bupropion Xl	Bupropion Hcl	58	17
Pravastatin Sodium	Pravastatin Sodium	58	17
Ventolin Hfa	Albuterol Sulfate	57	19
Pregabalin	Pregabalin	55	12
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	53	17
Donepezil Hcl	Donepezil Hcl	52	11
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	50	17
Torsemide	Torsemide	49	13
Atenolol	Atenolol	47	11
Ezetimibe	Ezetimibe	47	17
Jantoven	Warfarin Sodium	45	suppressed
Carvedilol	Carvedilol	44	18
Glimepiride	Glimepiride	44	14
Albuterol Sulfate Hfa	Albuterol Sulfate	43	27
Fluoxetine Hcl	Fluoxetine Hcl	42	11
Clopidogrel	Clopidogrel Bisulfate	40	suppressed
Buspirone Hcl	Buspirone Hcl	39	suppressed
Ozempic	Semaglutide	39	suppressed
Potassium Chloride	Potassium Chloride	39	11
Tramadol Hcl	Tramadol Hcl	39	14
Venlafaxine Hcl Er	Venlafaxine Hcl	36	suppressed
Montelukast Sodium	Montelukast Sodium	35	suppressed
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	33	suppressed
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	33	suppressed
Ultra-Fine Short Pen Needle	Pen Needle, Diabetic	33	11
Trulicity	Dulaglutide	32	suppressed
Januvia	Sitagliptin Phosphate	31	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	30	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	30	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	30	suppressed
Oxycodone Hcl	Oxycodone Hcl	29	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	28	suppressed
Paroxetine Hcl	Paroxetine Hcl	28	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	27	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	25	suppressed
Citalopram Hbr	Citalopram Hydrobromide	24	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	24	14
Divalproex Sodium	Divalproex Sodium	24	suppressed
Terazosin Hcl	Terazosin Hcl	24	suppressed
Toujeo Max Solostar	Insulin Glargine,hum.Rec.Anlog	24	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	23	suppressed
Prednisone	Prednisone	23	11
Fenofibrate	Fenofibrate Nanocrystallized	22	suppressed
Nystatin	Nystatin	22	suppressed
Propranolol Hcl	Propranolol Hcl	22	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	22	suppressed
Meloxicam	Meloxicam	21	suppressed
Ciclopirox	Ciclopirox	19	suppressed
Spironolactone	Spironolactone	19	suppressed
Dextroamphetamine-Amphetamine	Dextroamphetamine/Amphetamine	18	suppressed
Bupropion Hcl Sr	Bupropion Hcl	17	suppressed
Ketoconazole	Ketoconazole	17	suppressed
Nitroglycerin	Nitroglycerin	17	15
Amiodarone Hcl	Amiodarone Hcl	16	suppressed
Tizanidine Hcl	Tizanidine Hcl	16	suppressed
Xarelto	Rivaroxaban	16	suppressed
Invokana	Canagliflozin	15	suppressed
Lovastatin	Lovastatin	15	suppressed
Metronidazole	Metronidazole	15	suppressed
Novolin 70-30	Insulin Nph Hum/Reg Insulin Hm	15	suppressed
Pen Needle	Pen Needle, Diabetic	15	suppressed
Lorazepam	Lorazepam	14	suppressed
Alprazolam	Alprazolam	13	suppressed
Balsalazide Disodium	Balsalazide Disodium	13	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	13	suppressed
Myrbetriq	Mirabegron	13	suppressed
Novolog Flexpen	Insulin Aspart	13	suppressed
Prazosin Hcl	Prazosin Hcl	13	suppressed
Repatha Sureclick	Evolocumab	13	suppressed
Ropinirole Hcl	Ropinirole Hcl	13	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	13	suppressed
Atenolol-Chlorthalidone	Atenolol/Chlorthalidone	12	suppressed
Candesartan Cilexetil	Candesartan Cilexetil	12	suppressed
Fenofibrate	Fenofibrate	12	suppressed
Irbesartan	Irbesartan	12	suppressed
Naproxen	Naproxen	12	suppressed
Tolterodine Tartrate	Tolterodine Tartrate	12	suppressed
Zolpidem Tartrate Er	Zolpidem Tartrate	12	suppressed
Farxiga	Dapagliflozin Propanediol	11	suppressed
Fiasp Flextouch	Insulin Aspart (Niacinamide)	11	suppressed
Gavilyte-G	Peg3350/Sod Sulf,bicarb,cl/Kcl	11	11
Methylphenidate Hcl	Methylphenidate Hcl	11	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	11	suppressed
Olanzapine	Olanzapine	11	suppressed
Otezla	Apremilast	11	suppressed
Propranolol Hcl Er	Propranolol Hcl	11	suppressed
Topiramate	Topiramate	11	suppressed
Ultra-Fine Mini Pen Needle	Pen Needle, Diabetic	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error